TRIDENT-1 is a study evaluating the use of repotrectinib (a ROS-1 inhibitor/TKI in ROS-1) in ROS-1 mutant NSCLC patients [69]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.